Nucleic acids to treat cancer by MDRNA, Inc has been granted patent in China.
The People’s Republic of China (PRC) has issued a Notification of Granting Patent Rights for PRC 200480018784 which includes the use of nucleic acids, e.g., an siRNA, for the treatment of cancer.
The patent describes modulation of claudins, which are proteins implicated in tumor progression and metastasis.
MDRNA has a broad intellectual property estate that encompasses four key RNAi technology platforms: siRNA constructs, chemistry, nucleic acid delivery, and gene targets.
The MDRNA-owned siRNA constructs and chemistry include its proprietary UsiRNA construct, which is a duplex siRNA chemically modified with non-nucleotide acyclic monomers (UNAs), and is distinct from the standard siRNA construct used by others in the industry.
UsiRNAs are fully recognized by the RNAi machinery and provide for potent RNAi activity while specific placement of UNAs in a duplex siRNA minimizes potential off-target effects by the guide strand and reduces undesired passenger strand activity.
UsiRNAs escape the surveillance mechanisms associated with cytokine induction, and provide protection from nuclease degradation.
The MDRNA delivery platforms include DiLA2 and nanoparticle forming peptides.
DiLA2 is an MDRNA proprietary delivery platform of novel synthetic di-alkylated amino acid compounds used to make liposomal delivery formulations.
The DiLA2 platform enables MDRNA to tailor the charge, linker and acyl chains of amino acids in order to configure liposomes for delivery to target tissues of interest.
The platform is also designed to permit attachment of various peptides and other targeting molecules to improve a variety of delivery characteristics.
The MDRNA peptide nanoparticle platform includes exclusively in-licensed and developed IP surrounding the use of peptides for nanoparticle formulations that increase cellular uptake and endosomal release of siRNAs.
MDRNA is currently biopanning its patented phage display library to identify additional peptides for targeted delivery, cellular uptake and endosomal release of siRNA.
MDRNA owns or controls 7 issued or allowed patents, and has more than 40 pending patent applications, 126 pending foreign patent applications and 6 PCT applications.
“China’s pharmaceutical markets are growing nearly 20% a year,” said J. Michael French, President and CEO of MDRNA.
MDRNA is a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi).
MDRNA is developing of RNAi-based compounds and drug delivery technologies that together provide superior therapeutic options for patients.
MDRNA have developed capabilities in molecular biology, cellular biology, lipid chemistry, peptide chemistry, pharmacology and bioinformatics, which we are applying to a wide range of RNAi technologies and delivery approaches.
MDRNA is investing in new technologies that we expect to lead to safer and more effective RNAi-based therapeutics while aggressively building upon our broad and extensive intellectual property estate.
By combining expertise in siRNA science with proven delivery platforms and a strong IP position, MDRNA is well positioned as a leading RNAi-based drug discovery and development company.